Behind the Biogen-Stromedix Deal
February 16, 2012
February 16, 2012 | Earlier this week Biogen Idec acquired Stromedix, a biotechnology company focused on innovative therapies for fibrosis and organ failure, for up to $526m. Two of the venture capitalists behind Stromedix talk about the startup's history and the path to Biogen. The story, says Bruce Booth, is "one of the rare success stories of a big company externalizing R&D and then recapturing its value." Forbes